Back to results
US 2019/0117745 A1Published application
Drug delivery method
AssigneeRegents of the University of Minnesota
InventorsRonald A. Siegel, James Cloyd, Tate Winter, Mamta Kapoor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegents of the University of Minnesota
InventorsRonald A. Siegel, James Cloyd, Tate Winter, Mamta Kapoor
Estimating the term…
The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
1-29. (canceled)
A pharmaceutical dosage form comprising a soluble precursor of a pharmaceutically active compound and a soluble enzyme that converts said precursor to said pharmaceutically active compound, wherein said enzyme is not in contact with said precursor.
(canceled)
(canceled)
39-46. (canceled)
A pharmaceutical dosage form comprising:
A method for transporting and administering a compound to a mammal in need thereof, comprising:
Dependencies are inferred from the claim text.